The earnings result
Alnylam Pharmaceuticals reported earnings on 2022-04-28 for the fiscal quarter ending Mar/2022. Reported EPS of $2 compared with a consensus estimate of $-1.93, a beat on the source's earnings measure.
An EPS comparison describes one part of the release. Revenue, segment performance, cash conversion, guidance and the conference-call discussion require the original company disclosures; the result alone does not establish why the stock moved.
The market response
Price baseline: report-date close; announcement time unavailable. The source does not identify whether this report was before or after trading. These are subsequent daily returns, not a verified immediate earnings reaction.
The first measured session returned -6.80% from the stated baseline. The five-session return was -4.48%, and the 20-session return was -12.27%. SPY returned -5.26% across the corresponding window. Relative volume was 1.59 times the preceding 20-session average.
This edition is a source-based earnings-result and market-response analysis. A full financial-statement and conference-call dossier is not yet attached.